ADARx Pharmaceuticals, Inc. reported that LAV Biosciences Fund V, L.P., LAV Fund VI, L.P., LAV Fund VI Opportunities, L.P., and Yi Shi may be deemed to beneficially own an aggregate 11,858,655 common shares, or 11.1%, as of September 30, 2026. The funds directly owned 11,243,179, 307,738, and 307,738 shares, respectively; Yi Shi, their managing partner, may be deemed to share voting and dispositive power over those holdings. The percentages were calculated using 106,801,325 shares outstanding reported in ADARx’s September 28, 2026 IPO prospectus, assuming no exercise of the underwriters’ option. The reporting parties disclaim beneficial ownership of securities held by other parties.
ADARx Pharmaceuticals, Inc. is the issuer in a Schedule 13D reporting that SR One Fund I Aggregator, SR One Opportunities Fund I, SR One Co-Invest and AMZL collectively hold 9,936,661 shares of common stock, representing 9.3% of the class. The percentage is based on 106,801,325 shares reported outstanding as of September 28, 2026. The cover pages also report shared voting and dispositive power attributed to related managers and Simeon George.
At the September 28, 2026 IPO closing, SR One Fund I Aggregator bought 592,593 shares, SR One Opportunities Fund I bought 414,814 shares, and AMZL bought 592,593 shares, each at $17.00 per share. Previously purchased preferred shares held by several funds converted into common stock before the closing. SR One Fund I Aggregator, SR One Opportunities Fund I and SR One Co-Invest are subject to a 180-day lock-up after September 24, 2026, subject to exceptions and prior written underwriter consent. The funds also have registration rights under specified conditions.
ADARx Pharmaceuticals, Inc. (ADRX) has five OrbiMed entities reporting beneficial ownership of its common stock. OrbiMed Advisors LLC reported 14,913,764 shares with shared voting and dispositive power, representing 14% of the class. The disclosed fund holdings include 14,325,529 shares held by OrbiMed Private Investments VII, LP, 9,292,025 held by OrbiMed Israel Partners II, L.P., and 588,235 held by OrbiMed Genesis Master Fund, L.P. Some shares are attributed to related managers or general partners as well as the funds.
The funds also purchased shares in the IPO at $17.00 per share: OrbiMed Private Investments VII, LP bought 300,249, OrbiMed Israel Partners II, L.P. bought 61,516, and OrbiMed Genesis Master Fund, L.P. bought 588,235. Certain holders have Form S-1 and Form S-3 registration rights subject to stated thresholds. Lock-up agreements restrict transfers and related transactions until 180 days after the final IPO prospectus, subject to limited circumstances.
ADARx Pharmaceuticals, Inc. common stock is the subject of a beneficial-ownership report by BCLS Fund III Investments, LP, which reported holding 6,728,970 shares, approximately 6.3% of the class. It reported shared voting and dispositive power over 6,728,970 shares and zero sole voting or dispositive power. The 6.3% calculation uses 106,801,325 shares outstanding, as reported in ADARx’s prospectus filed September 28, 2026. Bain Capital Life Sciences Investors, LLC may also be deemed to share voting and dispositive power through its stated management chain.
ADARx Pharmaceuticals, Inc. director Erez Chimovits reported that OrbiMed Israel Partners II, L.P. purchased 61,516 common shares at $17 per share in the IPO on September 28, 2026. The entity’s Series A, Series B, Series B-1 and Series C preferred stock automatically converted into common stock at a 1-for-1.1717 ratio upon the IPO closing, without further consideration; each reported preferred-stock position was zero after conversion. OIP II held the securities directly. OrbiMed Advisors Israel II Limited exercised voting and investment power through a committee comprising Chimovits, Carl L. Gordon and David P. Bonita; all three disclaimed beneficial ownership, and Chimovits’s disclaimer was except to the extent of any pecuniary interest.
ADARx Pharmaceuticals, Inc. (ADRX) director and 10% owner Carl L. Gordon reported automatic conversion of preferred shares into 23,255,789 common shares upon the IPO closing. The shares were held directly by OrbiMed Private Investments VII, LP and OrbiMed Israel Partners II, L.P.; the conversion was on a 1-for-1.1717 basis without further consideration.
Those two entities and OrbiMed Genesis Master Fund, L.P. also purchased 950,000 common shares in the IPO on September 28, 2026, at $17 per share: 300,249, 61,516, and 588,235 shares, respectively. Gordon disclaims beneficial ownership of the reported securities except to the extent of any pecuniary interest.
ADARx Pharmaceuticals, Inc. (ADRX) had Preferred Stock held by OrbiMed-affiliated funds automatically converted into common shares upon the closing of its initial public offering on September 28, 2026, on a 1-for-1.1717 basis and without further consideration.
In the IPO, OrbiMed Private Investments VII, LP purchased 300,249 shares, OrbiMed Israel Partners II, L.P. purchased 61,516 shares, and OrbiMed Genesis Master Fund, L.P. purchased 588,235 shares, each at $17 per share. The shares were held directly by those funds, while related OrbiMed general partners and advisers reported indirect ownership. The footnotes identify Carl L. Gordon, W. Carter Neild, Geoffrey C. Hsu, David P. Bonita and Erez Chimovits as members of the applicable management committees and state that they disclaim beneficial ownership of the relevant fund shares. No Rule 10b5-1 plan is reported.
ADARx Pharmaceuticals, Inc. had indirect preferred-stock conversions reported by SR One Capital Management, LLC, a ten percent owner. The preferred securities were directly held by SR One Capital Fund I Aggregator, LP, SR One Capital Opportunities Fund I, LP and SR One Co-Invest III, LLC; upon ADARx’s IPO closing on September 28, 2026, they automatically converted into common stock on a 1-for-1.1717 reverse stock split basis, without further consideration. Separately, SR One Capital Fund I Aggregator, LP purchased 592,593 shares, SR One Capital Opportunities Fund I, LP purchased 414,814 shares and AMZL, LP purchased 592,593 shares, each at $17 per share. AMZL held 592,593 shares after its purchase. No Rule 10b5-1 plan is reported.
ADARx Pharmaceuticals, Inc. (ADRX) reports preferred-stock conversions and common-stock purchases on September 28, 2026, through entities associated with Simeon George, identified as a director and 10% owner. The conversions produced 3,334,938 and 1,113,666 common shares for SR One Capital Fund I Aggregator, LP; 1,538,691 for SR One Capital Opportunities Fund I, LP; and 1,667,468 and 169,001 for SR One Co-Invest III, LLC. Each preferred-stock derivative entry showed zero shares following conversion.
SR One Capital Fund I Aggregator, LP purchased 592,593 shares, SR One Capital Opportunities Fund I, LP purchased 414,814 shares, and AMZL, LP purchased 592,593 shares, each at $17.00 per share; AMZL, LP reported 592,593 shares following its purchase. The preferred shares automatically converted upon the IPO closing, without further consideration, on a 1-for-1.1717 reverse stock split basis. Transactions were indirect and attributed to the named entities; George disclaimed beneficial ownership of portions in which he had no pecuniary interest.
ADARx Pharmaceuticals, Inc. (ADRX) reported that LAV Biosciences Fund V, L.P., LAV Fund VI, L.P. and LAV Fund VI Opportunities, L.P.—each identified as a ten-percent owner—converted preferred stock into common stock on September 28, 2026, upon closing of the company’s IPO. The preferred stock converted automatically on a 1-for-1.1717 reverse stock split basis, without payment of further consideration.
LAV Biosciences Fund V converted 10,438,412 Series A, 1,953,774 Series B, 601,161 Series B-1 and 180,288 Series C preferred shares into 8,908,775, 1,667,469, 513,067 and 153,868 common shares, respectively. LAV Fund VI and LAV Fund VI Opportunities each converted 360,577 Series C preferred shares into 307,738 common shares.